Fuso, HuBit genomix to Co-develop Therapeutic, In-Vitro Diagnostic Drugs

Fuso Pharmaceutical Industries has announced that it has concluded a collaborative research agreement with HuBit genomix, a Tokyo-based biotech firm. Based on HuBit genomix's expertise in the genomic analysis of diabetes-related genes and related findings, Fuso and HuBit will strive to develop therapeutic and in-vitro diagnostic drugs for complications associated with diabetes including diabetic nephopathy.

Japan Corporate News (http://www.japancorp.net/Article.Asp?Art_ID=9400)